RECIST 1.1 in NSCLC Patients with EGFR Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Comparison with RECIST 1.0

Overview

Journal AJR Am J Roentgenol

Specialties Oncology
Radiology

Date 2013 Jun 25

PMID 23789698

Citations 22

Authors

Mizuki Nishino

Stephanie Cardarella

David M Jackman

Nikhil H Ramaiya

Michael S Rabin

Hiroto Hatabu

Pasi A Janne

Bruce E Johnson

Affiliations

Soon will be listed here.

Abstract

Objective: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 has been rapidly accepted in clinical trials as a standard measure to assess tumor response to therapy and is expected to improve response assessment, especially in genomically defined patients. The impact of RECIST 1.1 was compared with RECIST 1.0 in non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors.

Materials And Methods: Seventy patients with advanced NSCLC harboring sensitizing EGFR mutations treated with a first-line EGFR tyrosine kinase inhibitor were retrospectively studied. Tumor measurements and response assessment were performed using RECIST 1.0 and RECIST 1.1. The number of target lesions, the percentage change at the initial follow-up, best response, and time to progression were compared between RECIST 1.1 and RECIST 1.0.

Results: The number of target lesions identified using RECIST 1.1 was significantly lower compared with that using RECIST 1.0 (mean, 2.7 and 2.0, respectively; p < 0.0001; paired Student t test), with a decrease in 31 patients (44%). The initial proportional changes of the target lesion measurements had high correlation between the two criteria (R(2) = 0.8070), with concordant response assessment in 66 patients (94%). The best response showed almost perfect agreement (κw = 0.970). Time to progression (TTP) did not differ between the two criteria in 52 patients (74%), was longer by RECIST 1.1 in 15 patients (21%), and was shorter by RECIST 1.1 in three patients (4%).

Conclusion: RECIST 1.1 provided highly concordant response assessment with a decreased number of target lesions compared with RECIST 1.0 in advanced NSCLC patients harboring sensitizing EGFR mutations treated with an EGFR tyrosine kinase inhibitor. RECIST 1.1 altered TTP in 25% of patients compared with RECIST 1.0.

Citing Articles

Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.

Nishino M, Wang X, Ricciuti B, Tseng S, Park H, Alessi J Eur Radiol. 2023; 33(10):7284-7293.

PMID: 37099174 PMC: 10896107. DOI: 10.1007/s00330-023-09658-1.

AC099850.3/NCAPG Axis Predicts Poor Prognosis and is Associated with Resistance to EGFR Tyrosine-Kinase Inhibitors in Lung Adenocarcinoma.

Bao J, Wu Y, Zhang K, Qi H Int J Gen Med. 2022; 15:6917-6930.

PMID: 36061963 PMC: 9439153. DOI: 10.2147/IJGM.S365695.

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.

Vokes N, Chambers E, Nguyen T, Coolidge A, Lydon C, Le X J Thorac Oncol. 2022; 17(6):779-792.

PMID: 35331964 PMC: 10478031. DOI: 10.1016/j.jtho.2022.02.011.

Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.

Huicochea Castellanos S, Pagano A, Plodkowski A, Girshman J, Hellmann M, Rizvi H Lung Cancer. 2021; 161:60-67.

PMID: 34536733 PMC: 8683158. DOI: 10.1016/j.lungcan.2021.08.020.

Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.

Nishino M, Hong F, Ricciuti B, Hatabu H, Awad M JCO Precis Oncol. 2021; 5.

PMID: 34250409 PMC: 8232801. DOI: 10.1200/PO.20.00478.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Heon S, Yeap B, Lindeman N, Joshi V, Butaney M, Britt G . The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012; 18(16):4406-14. PMC: 3682221. DOI: 10.1158/1078-0432.CCR-12-0357. View

Jackman D, Yeap B, Sequist L, Lindeman N, Holmes A, Joshi V . Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(13):3908-14. DOI: 10.1158/1078-0432.CCR-06-0462. View

Sun J, Ahn M, Park M, Yi J, Kim T, Chung M . Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2009; 69(1):105-9. DOI: 10.1016/j.lungcan.2009.09.014. View

Arcila M, Oxnard G, Nafa K, Riely G, Solomon S, Zakowski M . Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011; 17(5):1169-80. PMC: 3070951. DOI: 10.1158/1078-0432.CCR-10-2277. View

Jackman D, Pao W, Riely G, Engelman J, Kris M, Janne P . Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2009; 28(2):357-60. PMC: 3870288. DOI: 10.1200/JCO.2009.24.7049. View

Nishino M, Jagannathan J, Krajewski K, ORegan K, Hatabu H, Shapiro G . Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012; 198(4):737-45. PMC: 3369700. DOI: 10.2214/AJR.11.7483. View

Heon S, Yeap B, Britt G, Costa D, Rabin M, Jackman D . Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010; 16(23):5873-82. PMC: 2999638. DOI: 10.1158/1078-0432.CCR-10-1588. View

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View

10.

Zhao B, James L, Moskowitz C, Guo P, Ginsberg M, Lefkowitz R . Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009; 252(1):263-72. PMC: 2797680. DOI: 10.1148/radiol.2522081593. View

11.

Janne P, Gurubhagavatula S, Yeap B, Lucca J, Ostler P, Skarin A . Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004; 44(2):221-30. DOI: 10.1016/j.lungcan.2003.12.014. View

12.

Kundel H, Polansky M . Measurement of observer agreement. Radiology. 2003; 228(2):303-8. DOI: 10.1148/radiol.2282011860. View

13.

Gazdar A . Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med. 2009; 361(10):1018-20. PMC: 3390194. DOI: 10.1056/NEJMe0905763. View

14.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

15.

Nishino M, Jackman D, Hatabu H, Yeap B, Cioffredi L, Yap J . New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010; 195(3):W221-8. PMC: 3130298. DOI: 10.2214/AJR.09.3928. View

16.

Nishino M, Guo M, Jackman D, DiPiro P, Yap J, Ho T . CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2010; 18(1):54-62. PMC: 3129593. DOI: 10.1016/j.acra.2010.08.021. View

17.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

18.

Nishino M, Jagannathan J, Ramaiya N, Van Den Abbeele A . Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010; 195(2):281-9. DOI: 10.2214/AJR.09.4110. View

19.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

20.

Nishino M, Jackman D, Hatabu H, Janne P, Johnson B, Van Den Abbeele A . Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011; 18(4):424-36. PMC: 3380440. DOI: 10.1016/j.acra.2010.10.020. View